MEDNAX (MD) Tops Q4 EPS by 14c ; Provides Outlook

MEDNAX (NYSE: MD) reported Q4 EPS of $0.51, $0.14 better than the analyst estimate of $0.37. Revenue for the quarter came in at $502 million versus the consensus estimate of $487.06 million.

Preliminary 2025 Outlook

On a preliminary basis, Pediatrix anticipates that its 2025 Adjusted EBITDA, as defined above, will be in a range of $215 million to $235 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
• TSS, Inc. (TSSI) Misses Q2 EPS by 1c
• Grandstand Limited (GRSD) Tops Q2 EPS by 5c; Offers Guidance